Pyrogallol Suppresses the Tumor Progression

ABSTRACT

Background: Pyrogallol, a bioactive compound derived from natural sources, is the focus of this study, aiming to investigate its anti-cancer properties against A549 lung cancer cells and uncover the underlying mechanisms. Purpose: This study seeks to elucidate the therapeutic potential of pyrogallol as a novel anti-cancer agent for NSCLC by targeting aerobic glycolysis and signal transducer and activator of transcription 2 (STAT2) signaling pathway. Background: Pyrogallol, a bioactive compound derived from natural sources, is the focus of this study, aiming to investigate its anti-cancer properties against A549 lung cancer cells and uncover the underlying mechanisms. Materials and Methods: A range of pyrogallol doses was administered to A549 cells, followed by a comprehensive analysis utilizing bioinformatic tools like Gene Expression Omnibus (GEO), GEO2R, WebGestalt, and the Search Tool for Interactions of Chemicals database. Assessments of cytotoxicity were conducted using 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide (MTT) and trypan blue assays post-treatment of A549 cells with pyrogallol. Cell cycle progression and cell death were evaluated via flow cytometry using Annexin V-fluorescein isothiocyanates/propidium iodide double staining. Network analysis helped identify pertinent signaling pathways, while RT-PCR validated mRNA expression changes in A549 cells. Auto dock docking studies were employed to gauge the binding affinity of pyrogallol with targets associated with the STAT2-mediated pathway. Results: Pyrogallol notably impeded the progression of A549 cells by prompting cell cycle arrest in the G0/G1 phase and fostering apoptosis. Network analysis highlighted its role in regulating metabolism, apoptosis, and STAT2 targets linked to lung tumorigenesis. RT-PCR validation affirmed the downregulation of genes associated with cell cycle and apoptosis targets. Furthermore, docking studies indicated a robust binding affinity between pyrogallol and the signaling targets within the STAT2 pathway. Pyrogallol displays the potential to halt the growth of lung cancer cells, indicating its promise as a viable treatment for this condition. Conclusion: These discoveries emphasize the need for additional research and clinical studies to fully harness its therapeutic benefits for lung cancer treatment.

KEYWORDS

• Pyrogallol
• non-small cell lung carcinoma
• anti-cancer properties
• cell cycle arrest
• apoptosis
• STAT2

Showing references and in-text citations exactly as published.

• DOI10.1177/09731296241242542Copy

RELATED ARTICLES

Matched on section and article type within this issue of Pharmacogn. Mag..

• Article · VOLUME 20, ISSUE 3The Beneficial Effects of Topical Cream Containing 17% of Herbal Extract on Skin Barrier Function: A Randomized Four-week TrialJi-Hyo Lyu, Soyeon Kim, Kang Kwon, Yongkuk Kim, Chanhun Choi, Hyunwoo Jeong, Hyungwoo Kim · pp. 1005–1012Original Research ArticleSame type: Article
• Article · VOLUME 20, ISSUE 3Study on the Mechanism of Anti-atopic Dermatitis by Herba Siegesbeckiae Based on System PharmacologyXiaowei Chen, YingYue Wang, Xin Zhang, Chang Liu, Chunxue You, Yubin Xu · pp. 1013–1022Original Research ArticleSame type: Article
• Article · VOLUME 20, ISSUE 3Assessment of Immunomodulatory Activity of AP-Bio® (KalmCold®), a Standardized Extract of Andrographis paniculata Using in vivo and ex vivo ModelsNehru Sai Suresh Chalichem, Prathiksha Nabhan, Bharathi Bethapudi, Nikita Agarwal, Sasi Kumar Murugan, Mundkinajeddu Deepak · pp. 727–732Original Research ArticleSame type: Article
• Article · VOLUME 20, ISSUE 3Induction and Characterization of Tetraploids from Astragalus membranaceus (Fisch.) Bge. SeedsShu-ling Zhang, Xin Zhang, Meng Wang, Li-jun Dong, Gui-xia Liu · pp. 733–744Original Research ArticleSame type: Article